Preliminary clinical analysis of concurrent chemoradiotherapy combined with nituzumab for inoperable locally advanced esophageal cancer
Zeng Cheng1,2, Yang Dan1, Du Rongxu1, Jiang Leilei1, Dong Xin1, Li Dongming1, Yu Rong1, Yu Huiming1, Shi Anhui1
1Department of Radiation Oncology, Peking University Cancer Hospital & Institute, Key Laboratory of Carcinogenesis and Translational Research, Peking University College of Clinical Oncology, Beijing 100142, China; 2Department of Oncology, General Hospital of Central Theater Command of Chinese People's Liberation Army, Wuhan 430070, China
Abstract：Objective The standard treatment for inoperable locally advanced esophageal cancer is concurrent chemoradiotherapy, but the survival was not satisfied. Nituzumab is a humanized IgG monoclonal antibody against EGFR. The purpose of this study is to investigate the toxicity and efficacy of concurrent chemoradiotherapy combined with nituzumab for locally advanced esophageal cancer. Methods We retrospectively reviewed the clinical data of locally advanced esophageal cancer who were treated with concurrent chemoradiotherapy combined with nituzumab in Peking University Cancer Hospital from June 2015 to June 2020. Kaplan-Meier method was used for analysis. Results Thirty Patients were enrolled this study.After a median follow-up of 22.5 months, The objective response rate was 93%. The 1-year, 2-year, 3-year overall survival rates were 83%, 57% and 41%,with the progression-free survival rates 75%, 47% and 32%, with the local-recurrence free survival rates 83%, 53% and 37%, with the metastasis-free survival rates 75%, 51% and 36%, respectively.The incidence of grade≥3 hematological toxicity was 32%. There were 16% patients experiencing grade≥3 esophagitis. Conclusion The preliminary result of concurrent chemoradiotherapy combined with nituzumab is effective and safe for patients with locally advanced esophageal cancer.
Zeng Cheng,Yang Dan,Du Rongxu et al. Preliminary clinical analysis of concurrent chemoradiotherapy combined with nituzumab for inoperable locally advanced esophageal cancer[J]. Chinese Journal of Radiation Oncology, 2021, 30(4): 353-356.
[1] NayanN, Bhattacharyya M, Jagtap VK, et al. Standard dose versus high dose radiotherapy with concurrent chemotherapy in esophageal cancer:a prospective randomized study[J]. South Asian J Cancer,2018,7(1):27-30. DOI:10.4103/sajc. sajc_178_17. [2] Zeng H, Chen W, Zheng R, et al. Changing cancer survival in China during 2003-15:a pooled analysis of 17 population-based cancer registries[J]. Lancet Glob Health, 2018, 6(5):e555-e567. DOI:10.1016/S2214-109X (18)30127-X. [3] Yang YH, Zhou WW, Wu JD, et al. Antitumor activity of nimotuzumab in combination with cisplatin in lung cancer cell line A549 in vitro[J]. Oncol Lett, 2018, 15(4):5280-5284. DOI:10.3892/ol.2018.7923. [4] Castro C, Peleteiro B, Morais S, et al. An explanatory and predictive model of the variation in eal cancer incidence on the basis of changes in the exposure to risk factors[J]. Eur J Cancer Prev, 2018, 27(3):213-220. DOI:10.1097/CEJ.00 00000000000422. [5] Rice TW, Ishwaran H, Ferguson MK, et al. Cancer of the esophagus and esophagogastric junction:an eighth edition staging primer[J]. Thorac Oncol, 2017, 12(1):36-42. DOI:10.1016/j.jtho.2016.10.016. Epub 2016 Oct 31. [6] Eisenhauer EAJ, Therasse PJ, Bogaerts J, et al. New response evaluation criteria in solid tumours:revised RECIST guideline (version 1.1)[J]. EurJ cancer, 2009, 45(2):228-247. DOI:10.1016/j.ejca.2008.10.026. [7] Van Meter EM, Garrett-Mayer E, Bandyopadhyay D. Dose-finding clinical trial design for ordinal toxicity grades using the continuation ratio model:an extension of the continual reassessment method[J].Clin Trials, 2012, 9(3):303-313. DOI:10.1177/174077451244 3593. [8] Zuo TT, Zheng RS, Zeng HM, et al. Incidence and trend analysis of esophageal cancer in China[J]. Chin J Oncol, 2016, 38(9):703-708. DOI:10.3760/cma.j.issn.0253-3766.2016.09.013. [9] Zhang SW, Zheng RS, Zuo TT, et al. Mortality and survival analysis of esophageal cancer in china[J]. Chin J Oncol, 2016, 38(9):709-715. DOI:10.3760/cma.j.issn. 0253-3766.2016.09.014. [10] Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer:long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation therapy oncology group[J].JAMA, 1999, 281(17):1623-1627. DOI:10.1001/jama.281.17.1623. [11] CSCO. Guidelines for the diagnosis and treatment of esophageal cancer (2020 edition)[M]. Beijing:People's Medical Publishing House, 2020. [12] Lyu J, Li T, Wang Q, et al. Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for stage ⅠV esophageal squamous cell carcinoma:a retrospective controlled study[J]. Radiat Oncol, 2018, 13(1):233. DOI:10.1186/s13014-018-1183-y. [13] 郑荣寿,孙可欣,张思维,等.2015年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志,2019, 41(1):19-28. DOI:10.3760/cma. j. is sn.0253-3766.2019.01.005. Zheng RS, Sun KX, Zhang SW, et al. Report of cancer epidemiology in China, 2015[J]. Chin J Oncol, 2019, 41(1):19-28. DOI:10.3760/cma.j.issn.0253-3766.2019.01.005. [14] 周家琛,郑荣寿,张思维,等. 2000—2015年中国肿瘤登记地区食管癌发病及年龄变化趋势[J]. 中华肿瘤防治杂志, 2020, 27(18):1437-1442. DOI:10.16073/j.cnki.cjcpt.2020.18.01. Zhou JS, Zheng RS, Zhang SW, et al. Analysis on the trend of esophageal cancer incidence and age change in cancer registration areas of China, 2000 to 2015[J]. Chin J Cancer Prev Treat, 2020, 27(18):1437-1442. DOI:10.16073/j.cnki.cj cpt.2020.18.01. [15] Zhang SW, Zheng RS, Zuo TT, et al. Mortality and survival analysis of esophageal cancer in china[J]. Chin J Oncol, 2016, 38(9):709-715. DOI:10.3760/cma.j.issn.0253-3766.2016.09.014. [16] Zhen Y, Guanghui L, Xiefu Z, et al. Knockdown of EGFR inhibits growth and invasion of gastric cancer cells[J]. Cancer Gene, 2014, 21(11):491-497. DOI:10.1038/cgt.2014.55. [17] Song J, Shi W, Zhang Y, et al. Epidermal growth factor receptor and B7-H3 expression in esophageal squamous tissues correlate to patient prognosis[J]. Oncol Targets Ther, 2016, 9:6257-6263. DOI:10.2147/OTT. S111691.eCollection 2016. [18] Yu W, Yang X, Chu L, et al. Prognostic value of EGFR family expression in lymph node-negative esophageal squamous cell carcinoma patients[J]. Pathol Res Pract, 2018, 214(7):1017-1023. DOI:10.1016/j.prp.2018.04.017. [19] Mazorra Z, Chao L, Lavastida A, et al. Nimotuzumab:beyond the EGFR signaling cascade inhibition[J]. Semin Oncol, 2018, 45(1-2):18-26. DOI:10.1053/j.seminoncol.2018.04.008.
2021, Vol. 30 
